辉瑞曾开发另一种口服GLP-1药物lotiglipron，但在临床试验中发现其可能具有肝毒性，公司最终在2023年6月终止开发该药物。 封面图片来源：视觉中国 ...

2月4日，辉瑞公布了2024年业绩，第四季度营收177.63亿美元，同比增长21%，全年实现营收636.27亿美元，同比增长7%，若排除新冠 ...

As well as, falling in tandem with the release of Pfizer’s annual earnings report, which reflected revenues of $63.6 billion. In the announcement, Bourla stated: “I’m excited for what’s ...

Good day, everyone, and welcome to Pfizer's Fourth Quarter 2024 Earnings Conference Call. Today's call is being recorded. At this time, I would like to turn the call over to Francesca DeMartino ...

Pfizer (PFE) reported fourth quarter and full-year 2024 earnings results Tuesday, narrowly beating Wall Street expectations and its stock remained flat after market open. Pfizer reported $63.6 ...

After a period of unsteady sales for its key COVID-19 products, Pfizer now sees COVID-related revenue volatility as “largely in the past.” In an investor presentation (PDF) Tuesday ...

Pfizer has ended development of a B7-H4-directed antibody-drug conjugate (ADC), triggering a $1 billion impairment charge. The Big Pharma disclosed the blow alongside a $200 million charge linked ...

Diluted EPS in a Range of $2.80 to $3.00 The fourth-quarter 2024 earnings presentation and accompanying prepared remarks from management as well as the quarterly update to Pfizer’s R&D pipeline ...

With just one asset in weight loss moving through the clinic, Pfizer targets the space for potential dealmaking, as well as bringing assets over from China. As Pfizer beat analyst expectations for ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) reported financial results for fourth-quarter and full-year 2024 and reaffirmed its 2025 financial guidance (5) provided on December 17, 2024. The ...

Merck is battling selling pressure, but strong analyst targets suggest upside potential. Pfizer faces a bearish trend with minimal upside, though analysts expect a moderate gain. Get two weeks of ...

NEW YORK, Feb 3 (Reuters) - Health experts are seeing signs of a much smaller wave of U.S. COVID-19 cases this winter than in previous years, which could put additional pressure on Pfizer (PFE.N ...